Lege Artis Medicinae

[Health-economic analysis of diseases related to disturbed neonatal adaptation: a cost of illness study]

BONCZ Imre1, KOVÁCS L. Gábor2, ERTL Tibor3, ÁGOSTON István1, MOLICS Bálint1, BÓDIS József1,3

APRIL 20, 2013

Lege Artis Medicinae - 2013;23(03-04)

[OBJECTIVES - The aim of our study is to perform a health-economic analysis of diseases related to disturbed neonatal adaptation by assessing the burden of health care costs in Hungary. DATA AND METHODS - Data were derived from the financial dataset of the National Health Insurance Fund Administration (OEP) covering year 2009. Four diseases were included in the analysis: polycystic ovary syndrome (E2820), retinopathy of prematurity (H3510), hyperstimulation of ovaries (N9810) and respiratory distress syndrome of the newborn (P2200). RESULTS - The annual health insurance costs of the assessed diseases were the following: polycystic ovary syndrome: 78.9 million Hungarian Forints (HUF) or 281 160 Euro (EUR), retinopathy of prematurity: 41.3 million HUF (147 090 EUR), hyperstimulation of ovaries: 8.7 million HUF (30 839 EUR) and respiratory distress syndrome of the newborn: 1.562 million HUF (5 567 336 EUR). We found by far the highest annual per capita health insurance expenditure for respiratory distress syndrome of the newborn (1,43 million HUF or 5098 EUR/patient/year). Hyperstimulation of ovaries (58 073 HUF or 207 EUR/patient/year), retinopathy of prematurity (19 513 HUF or 70 EUR/patient/year) and polycystic ovary syndrome (7679 HUF or 27 EUR/patient/year) was associated with significantly lower annual per capita health insurance expenditure. CONCLUSIONS - The diseases related to disturbed neonatal adaptation have substantial annual health insurance expenditures (1 689 million HUF or 6.02 million EUR) and of these diseases respiratory distress syndrome of the newborn has the highest burden of disease.]


  1. Pécsi Tudományegyetem, Egészségtudományi Kar, Egészségbiztosítási Intézet
  2. Pécsi Tudományegyetem, Általános Orvostudományi Kar, Laboratóriumi Medicina Intézet, Pécs
  3. Pécsi Tudományegyetem, Általános Orvostudományi Kar, Szülészeti és Nôgyógyászati Klinika



Related contents

Lege Artis Medicinae

[Cost minimization analysis of basal insulin analogues in the treatment of type 2 diabetes]

MERÉSZ Gergő, TABÁK Gy. Ádám, KALÓ Zoltán

[INTRODUCTION - Basal insulin analogues are essential drugs for the treatment of type 2 diabetes mellitus. Basal insulin analogues have been shown to reduce the frequency of hypoglycaemia versus NPH insulin, and thus may be beneficial in the treatment of type 2 diabetes. Here we present a cost-minimisation analysis of basal insulin analogues, comparing insulin glargine and insulin detemir available in Hungary. METHODS - A literature review was conducted to identify randomized, controlled clinical trials with a duration of 12 weeks or more in which a direct comparison of insulin glargine and insulin detemir was made in patients with type 2 diabetes. In a meta-analysis of the eligible trials, the following endpoints were investigated: metabolic status, body weight, frequency of hypoglycaemia, insulin doses administered and the number of insulin injections required. If a high heterogeneity (I2>75%) was found, meta-regression was performed to identify the underlying reasons. The funder’s perspective was applied in the cost-minimization analysis by taking into account the cost of the drug and of medical devices necessary for its administration, based on the daily number of insulin injections. RESULTS - No further studies were found in addition to those included in a metaanalysis published by The Cochrane Library. On the basis of three eligible studies, insulin detemir was injected more frequently compared with glargine (weighted mean difference: 0.42 95% CI 0.14-0.69 injections/day). High heterogeneity was present in case of two endpoints: the incidence of overall hypoglycaemia per patient-year (I2=83%), and daily basal insulin dose in units per body weight (I2=94%). The reason for the high heterogeneity in hypoglycaemia rates was not identified by meta-regression; however, the difference in insulin doses per body weight was negatively associated with body weight (-0.027 IU/kg per 1 kg, 95%CI: -0.051; -0.004). On the basis of the present meta-analysis and meta-regression, our calculations suggest that treating an average weight (90 kg) patient with type 2 diabetes with insulin glargine would result in an annual cost reduction of 93 452 HUF compared with insulin detemir by employing gross public drug prices. CONCLUSION - On the basis of the available clinical evidence, insulin glargine might be a cost-saving alternative of insulin detemir in an average-weight patient with type 2 diabetes. In an era of scarce resources, the role of therapeutic alternatives offering cost savings with the same efficacy become more important. The generalisability of our conclusions might be influenced by potential differences in the manufacturers’ claw-back rate of detemir vs glargine insulin.]

Clinical Neuroscience

[Survey of adults with epilepsy in Hungary: health related quality of life and costs]

PÉNTEK Márta, BERECZKI Dániel, GULÁCSI László, MIKUDINA Boglárka, ARÁNYI Zsuzsanna, JUHOS Vera, BAJI Petra, BRODSZKY Valentin

[Background and purpose - Disease burden of epilepsy in Hungary is underexplored. The aim of our study was to assess the quality of life and costs of adults with epilepsy. Methods - Cross-sectional questionnaire survey was performed in two hospital based outpatient neurology centres involving consecutive patients with epilepsy. Demography, clinical characteristics, health status (EQ-5D) and health care utilisation in the past 12 months were surveyed. Cost calculation was performed from the societal perspective. Results - Altogether 100 patients (women 58%) were involved, their mean age was 37.6 (SD=12.5) years. Disease duration was 15.0 (SD=12.1) years on average and 22 (22%) patients were disability pensioners. The EQ- 5D score was mean 0.83 (SD=0.24) which is significantly lower than the age-matched population norm (p=0.017). Pain/discomfort and anxiety/depression are the most problematic health dimensions. The annual cost per patient was mean 2421 (SD=3249) Euros (679 397 SD=911 783 HUF; conversion: 1 Euro=280.6 HUF), distribution between direct medical, direct non-medical and indirect costs was 33%, 18% or 49%. Patients with seizure in the past 12 months have higher cost on avergare than the asymptomatic subsample (3119 vs. 988 Euros/patient/year; 935 481 vs. 277 209 HUF/patient/year). Conclusion - Adults with epilepsy have significantly worse health status by the EQ-5D than the gender and age matched Hungarian general population. Disease related costs are significant especially in cases with seizure, productivity loss related costs are dominant. Our study provides basic data for clinical and sustainable health care financing decisions.]

Lege Artis Medicinae

[Comment to the article titled “Exploratory study of outcomes of blood sample mass examinations by rank correlations”]